What’s the value of bringing a drug to market first? In some
cases, it may be less than you think.
There has been a long-running debate in the pharmaceutical
industry about the value of being first to market. Companies spend considerable
resources seeking to increase the odds of beating their competitors to market
and often hassle about the commercial disadvantage of being late. In the
high-stakes race to market for a novel drug class, companies firmly believe
that every month of lead time ahead of a competitor is significant. . The
industrial R&D in the country should actually be focused on this phase of
technology development where laboratory models are scaled up and converted into
commercially viable products/processes. Evolving a laboratory-proven idea into
an implementable technology is a kind of effort, which the academic community
does not appear to be fully geared towards, at least at present.
It’s not quite that simple. Analysis of Pharmaceutical
Research in India confirms a weak first-to-market advantage on average, but
with significant nuances dependent on market context. In many instances, the first-mover
advantage actually vanishes, particularly when the lead time is short or when
the first mover is a small company. At Ciron the team of talented scientist
keeps their core focus on the upcoming problems & solutions, the
revolutions invention in pharmaceutical world is always the prime target for
Ciron. To know more about the Ciron world visit http://www.cironpharma.in/
No comments:
Post a Comment